An anti-CD20 monoclonal antibody that targets B cells to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ malignant and normal B lymphocytes via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC by NK/macrophages, complement activation (CDC), and CD20-mediated apoptotic signaling.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T-cell therapy designed to kill HER2 (ERBB2)-expressing tumor cells.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T cells that recognize HER2 (ERBB2) via a 1XX CAR, triggering T-cell activation and cytotoxic killing of HER2+ tumor cells. Engineered features include CXCR2 to enhance trafficking, a TGFβ signal-redirection receptor to counter immunosuppression, CD38 knockout for persistence, an IL-7/IL-7R fusion to support T-cell stemness, TCR removal to reduce GVHD risk, and a high-affinity non-cleavable CD16a to enable antibody-dependent cellular cytotoxicity when a compatible therapeutic antibody is administered.
YES
DIRECT
HER2-expressing cells are recognized by the HER2-specific CAR on FT825 T cells, triggering T-cell activation and cytolytic killing (perforin/granzyme and death receptor pathways); hnCD16 can also mediate ADCC if a compatible anti-HER2 antibody is present.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T-cell therapy designed to kill HER2 (ERBB2)-expressing tumor cells.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T cells that recognize HER2 (ERBB2) via a 1XX CAR, triggering T-cell activation and cytotoxic killing of HER2+ tumor cells. Engineered features include CXCR2 to enhance trafficking, a TGFβ signal-redirection receptor to counter immunosuppression, CD38 knockout for persistence, an IL-7/IL-7R fusion to support T-cell stemness, TCR removal to reduce GVHD risk, and a high-affinity non-cleavable CD16a to enable antibody-dependent cellular cytotoxicity when a compatible therapeutic antibody is administered.
NO
INDIRECT
FT825 does not target cells for expressing an IgG1 Fc region. Its engineered CD16a binds the Fc of a therapeutic antibody that is bound to a tumor antigen, bridging and activating the T cell to kill the antibody-opsonized, antigen-positive cells via T‑cell cytotoxicity (perforin/granzyme).
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T-cell therapy designed to kill HER2 (ERBB2)-expressing tumor cells.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T cells that recognize HER2 (ERBB2) via a 1XX CAR, triggering T-cell activation and cytotoxic killing of HER2+ tumor cells. Engineered features include CXCR2 to enhance trafficking, a TGFβ signal-redirection receptor to counter immunosuppression, CD38 knockout for persistence, an IL-7/IL-7R fusion to support T-cell stemness, TCR removal to reduce GVHD risk, and a high-affinity non-cleavable CD16a to enable antibody-dependent cellular cytotoxicity when a compatible therapeutic antibody is administered.
NO
INDIRECT
FT825 CAR T cells kill via HER2-directed CAR engagement (perforin/granzyme). The TGF-β1 signal‑redirection receptor only modulates signaling and does not mediate target-cell recognition or killing; cells expressing TGF-β1 are not specifically killed unless they also express HER2.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T-cell therapy designed to kill HER2 (ERBB2)-expressing tumor cells.
Off-the-shelf, allogeneic iPSC-derived HER2-directed CAR T cells that recognize HER2 (ERBB2) via a 1XX CAR, triggering T-cell activation and cytotoxic killing of HER2+ tumor cells. Engineered features include CXCR2 to enhance trafficking, a TGFβ signal-redirection receptor to counter immunosuppression, CD38 knockout for persistence, an IL-7/IL-7R fusion to support T-cell stemness, TCR removal to reduce GVHD risk, and a high-affinity non-cleavable CD16a to enable antibody-dependent cellular cytotoxicity when a compatible therapeutic antibody is administered.
NO
INDIRECT
FT825 kills HER2+ cells via CAR T-cell cytotoxicity (perforin/granzyme) and can mediate ADCC via CD16a with a compatible antibody. The TGF-β signal‑redirection receptor only modulates T-cell signaling in response to TGF‑β2; it does not target TGF‑β2–expressing cells for killing.